Context Therapeutics Inc. (NASDAQ:CNTX) Stock Moves Up Ahead Of Key Trial Data

Context Therapeutics Inc. (NASDAQ:CNTX) up 10% after the company announced that it would present onapristone extended-release (ONA-XR) clinical data at the virtual 2021 San Antonio Breast Cancer Symposium taking place from December 7-10, 2021.

Market Stats

On Friday, CNTX stock surged 9.90% at $4.89 with more than 7.95 million, compared to its average volume of 4.22 million shares. The stock has moved within a range of $4.8000 – 5.9000 after opening trading at $4.99.

Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium

CEO Martin Lehr said they are delighted to present ONA-XR data from various cancer stages at SABCS that includes ONAWA clinical trial data of ONA-XR in breast cancer and highlights the current clinical studies of clinical studies ONA-XR in breast cancer that has metastasized. In addition, Lehr said they are looking forward to interacting wit5h the oncology community during the SABCS and discussing ONA-XR’s potential in helping breast cancer patients.

The company also announced the dosing of the first patient in the phase 2 OnapriStone in CoMbInation with FuLvestrant for ER positive patients and HER2- metastatic Breast Cancer after Progression on Endocrine therapy (the SMILE Study). Wisconsin Oncology Network conducted the study to evaluate the progesterone receptor antagonist ONA-XR’s effect in combination with Faslodex for men and women with PR+, ER+ metastatic breast cancer. So in the coming weeks, CNTX is worth watching.

Key Quote

“We are pleased that ONA-XR data from multiple stages of breast cancer will be presented at SABCS including the first clinical data from the ONAWA trial, sponsored by the Spanish cancer research group SOLTI, of ONA-XR in early-stage breast cancer and updates from two ongoing clinical trials of ONA-XR in metastatic breast cancer. We look forward to connecting with the oncology community at SABCS, to discuss advancements in breast cancer and further highlight the potential of ONA-XR to make a meaningful impact in the lives of people living with breast cancer,” said Martin Lehr, CEO of Context Therapeutics.

Traders Corner

CNTX stock is trading above the 20-Day and 50-Day Moving averages of $5.52 and $5.70 respectively. Moreover, the stock is trading above the 200-Day moving average of $5.70. The stock is down 2% in the past month.